MGLL and Cognitive impairment: Of reference, increased endocannabinoid 2-arachidonoylglycerol (2-AG) by inhibiting the action of monoacylglycerol lipase (MAGL) prevented PGE2 production, neuroinflammation-associated Aβ42 accumulation, and neurodegeneration, indicating that it is a good therapeutic target for relieving cognitive impairment [45].